Publications

Abstract Background: Little is known about the potential benefits or harms of statins on physical function among people with HIV (PWH). Methods: REPRIEVE was a double-blind randomized controlled […]

Abstract Background Coronary plaque is common among people with HIV (PWH) with low-to-moderate traditional atherosclerotic cardiovascular disease (ASCVD) risk. Objectives The purpose of this study was […]

Abstract The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) (Aug. 24 issue of NEJM) was a global trial that assessed pitavastatin calcium as compared […]

Abstract Background People with HIV (PWH) have a high burden of coronary plaques; however, the comparison to people without known HIV (PwoH) needs clarification. Objectives The […]

Abstract Background  Coronary artery disease (CAD) is a leading cause of death among the 38.4 million people with HIV globally. The extent to which cardiovascular polygenic risk […]

Abstract Importance  Cardiovascular disease (CVD) is increased in people with HIV (PWH) and is characterized by premature noncalcified coronary plaque. In the Randomized Trial to Prevent Vascular […]

Abstract Key Points Clonal hematopoiesis of Indeterminate Potential (CHIP), the clonal expansion of myeloid cells with leukemogenic mutations, results in increased coronary artery disease (CAD) risk. […]

Abstract Background Cytomegalovirus (CMV) seropositivity is associated with poor outcomes, including physical function impairment, in people without HIV. We examined associations between CMV IgG titer and […]

Abstract Plasma VEGF coreceptor neuropilin-1 (NRP-1) had the largest association with coronary plaque in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) proteomics analysis. […]